Printer Friendly

LIDAK PHARMACEUTICALS' LEAD DRUG CANDIDATE COMPLETES FIRST PHASE II CLINICAL TRIAL

 LA JOLLA, Calif., July 20 /PRNewswire/ -- LIDAK Pharmaceuticals (NASDAQ: LDAKA) announced today that a Phase II pilot study of the efficacy of the topical anti-herpes drug, LIDAKOL(TM), has been completed. This study, which was conducted in Europe, was managed and analyzed by LIDAK's European partner, Brocades Pharma, b.v.
 Preliminary results in the double-blind, placebo-controlled study in patients with recurrent herpes labialis, commonly known as fever blisters or cold sores, showed that application of LIDAKOL at an early stage of a recurrence significantly reduced the duration of the episode. The LIDAKOL-treated group had an average outbreak duration of 3.4 days versus an average of 6.6 days in the placebo-treated group. A full report of the study results will be prepared for presentation at a future scientific meeting and for publication in an appropriate scientific journal.
 LIDAKOL is a topically administered anti-viral cream that is being tested on patients with recurrent oral or genital herpes. Two other ongoing Phase II clinical trials investigating topical LIDAKOL, being managed by LIDAK in the United States, were initiated in November 1992 and April 1993. Additional efficacy data required for eventual marketing approval will be generated in future Phase III trials to be conducted in both the U.S. and Europe.
 Brocades Pharma is part of Yamanouchi Pharmaceutical Co. Ltd. and is headquartered in The Netherlands. Brocades is investigating the development and regulatory approvals of LIDAKOL in Europe as part of a collaborative agreement with LIDAK which commenced in November 1991 that also covers commercialization of the drug. Dermatological products constitute a large component of the drug sales of Brocades Pharma.
 LIDAK Pharmaceuticals is developing therapeutic products against virally caused diseases, inflammatory disorders and cancer. The Company's initial focus is on the commercialization of LIDAKOL as a treatment for herpes and other indications. The company is also developing its Large Multivalent Immunogen (LMI) technology for potential new therapies against cancer and viral diseases.
 -0- 7/20/93
 /CONTACT: David H. Katz, M.D., president and CEO of LIDAK Pharmaceuticals, 619-450-1538; or Fern Lazar or Kate de Santis of Dewe Rogerson, 212-688-6840, for LIDAK Pharmaceuticals/
 (LDAKA)


CO: Lidak Pharmaceuticals ST: California IN: MTC SU:

PS-LG -- NY012 -- 6597 07/20/93 08:59 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1993
Words:370
Previous Article:WHEELABRATOR ENVIRONMENTAL SYSTEMS ACQUIRES HUDSON LUMBER COMPANY WOOD-FIRED COGENERATION PROJECT
Next Article:MOBIL CONTRIBUTES $100,000 TO AID FLOOD VICTIMS, DONATES TRASH BAGS FOR CLEAN-UP
Topics:


Related Articles
NEW ANTI-VIRAL COMPOUND REPORTED BY LIDAK PHARMACEUTICALS
LIDAK INITIATES PHASE II CLINICAL TRIAL FOR ORAL HERPES
LIDAK REPORTS ADDITIONAL PHASE II GENITAL HERPES STUDY RESULTS LIDAKOL REDUCED PAIN ASSOCIATED WITH EPISODES
LIDAK PHARMACEUTICALS ANNOUNCES EARLY COMPLETION OF PHASE 3 LIDAKOL CLINICAL TRIAL IN EUROPE AND COMPLETION OF PHASE 2 IN THE U.S.
LIDAK PHARMACEUTICALS INITIATES A THIRD PHASE 3 CLINICAL TRIAL OF LIDAKOL IN THE UNITED STATES FOR EARLY TREATMENT OF ORAL HERPES
LIDAK PHARMACEUTICALS RECEIVES FDA CLEARANCE TO PROCEED WITH CANCER THERAPY CLINICAL TRIALS
LIDAK PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM PHASE 3 EUROPEAN CLINICAL TRIAL
LIDAK PHARMACEUTICALS COMPLETES PATIENT TREATMENTS IN THREE PHASE 3 LIDAKOL TRIALS IN U.S. AND CANADA
LIDAK PHARMACEUTICALS COMMENCES PHASE 1/PHASE 2 TRIAL OF HUMAN MELANOMA VACCINE
LIDAK PHARMACEUTICALS REPORTS NEW POTENTIAL EARLY-ACTING ANTI-INFLAMMATORY PEPTIDES AT INTERNATIONAL MEETING

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters